Application Notes: General

Prevent contamination in pipetting with best practices to avoid pipette-to-sample, sample-to-pipette, and sample-to-sample risks. Learn how filter tips and sterile techniques safeguard results.

Free enzymes suffer from inconsistent performance and are difficult to recover and reuse. Immobilizing enzymes on silica resin offers a practical and efficient solution for biocatalysis reactions, enabling reproducibility, consistency, and cost-effectiveness at scale. Grace’s DAVISIL® silica resins offer a smart solution for immobilizing enzymes and are available in a wide range of pore sizes, particle sizes and chromatography phases. Discover how solid silica supports from Grace can transform your process.

TFA in LC causes baseline noise due to UV absorbance, making pump pulsation visible and raising LOD/LOQ. Increasing mixer volume stabilizes baseline.

By using a streamlined native hydrophobic interaction chromatography-mass spectrometry (HIC-MS) method, MS-compatible ammonium tartrate salts can enhance the separation and detection of antibody-drug conjugate (ADC) drug-to-antibody ratio (DAR) species. This advanced approach overcomes historical coupling difficulties and supports rapid, high-resolution DAR profiling and real-time monitoring for improved ADC characterization and manufacturing control.

Poster showcasing Pfizer's use of ACD/Labs’ method development software to automate method variation simulations. Highlights key tools and features that streamline method transfer and boost efficiency through automation.

This poster presents an example of the analysis of all 17 explosives listed in EPA 8330B using atmospheric pressure chemical ionization liquid chromatography mass spectrometry (APCI-LC-MS/MS), which allowed for more sensitive and selective analysis than PDA detection. In addition, MRM analysis provides an extra layer of confirmation based on the unique fragmentation of each compound.

John Yates’ lab is using MOBILion’s Parallel Accumulation Mobility Aligned Fragmentation (PAMAF) technology to enhance the DeGlyPHER workflow, which enables detailed, site-specific analysis of N-glycosylation in viral spike proteins such as SARS-CoV-2. This method combines sequential deglycosylation with high-sensitivity LC-MS to quantify glycan occupancy and processing, offering insights into the relationship between glycosylation and immune response. DeGlyPHER has been applied to over 200 vaccine candidates, including those for HIV, influenza, and Ebola, advancing understanding of glycoprotein-based immunogen design. This executive summary explains how DeGlyPHER is transforming vaccine development in real time, driving progress toward more effective and consistent immunization strategies, and delivering a more sensitive and high-throughput approach compared to traditional glycoproteomic methods.